Playback speed
10 seconds
Durvalumab +/- Trimelimumab vs. SoC in the 2nd-Line Treatment for Recurrent/Metastatic H&N Squamous Cell Carcinoma Didn't Improve OS
15 views
January 7, 2020
Comments 0
Login to view comments.
Click here to Login